Importantly, UBC13 expression has been reported to correlate with survival of ovarian cancer patients after paclitaxel-containing therapy, leading to the concept that a UBC13-DNMT1-CHFR pathway modulates paclitaxel sensitivity [35] and providing further impetus for assessing the relationship between CHFR and ovarian cancer outcome in the present study. The gene discussed is CHFR; the disease is ovarian carcinoma.